Novel Insights on the Management of Pain: Highlights From the ‘Science of Relief’ Meeting

References

• ‘Disposizioni per garantire l’accesso alle cure palliative e alla terapia del dolore’ (2019). www.parlamento.it/parlam/leggi/10038l.htm
   Google Scholar
• Montes A , AguilarJL , BenitoMC , CabaF , MargaritC; Acute Pain Group of the Spanish Pain Society (SED). Management of postoperative pain in Spain: a nationwide survey of practice. Acta Anaesthesiol. Scand.61(5), 480–491 (2017).
   PubMed Web of Science ®Google Scholar
• Fang LY , XuYC , LinDN , JinJF , YanM. Attitude and intention regarding pain management among Chinese nursing students: a cross-sectional questionnaire survey. Pain Manag. Nurs.18(4), 250–259 (2017).
   PubMed Web of Science ®Google Scholar
• Shoqirat N , MahasnehD , Al-KhawaldehO , SinghC. Postoperative patients in Jordan: pain prevalence, characteristics, beliefs, and satisfaction. Pain Manag. Nurs.20(3), 239–244 (2019).
   PubMed Web of Science ®Google Scholar
• Breivik H , CollettB , VentafriddaV , CohenR , GallacherD. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J. Pain10(4), 287–333 (2006).
   PubMed Web of Science ®Google Scholar
• Dureja GP , JainPN , ShettyNet.al Prevalence of chronic pain, impact on daily life, and treatment practices in India. Pain Pract.14(2), E51–E62 (2014).
   PubMed Web of Science ®Google Scholar
• Dickenson AH , KressHG. Tapentadol: a new option for the treatment of cancer and noncancer pains. J. Pain Res.12, 1509–1511 (2019).
   PubMed Web of Science ®Google Scholar
• Sprenger C , FinsterbuschJ , BüchelC. Spinal cord-midbrain functional connectivity is related to perceived pain intensity: a combined spino-cortical fMRI study. J. Neurosci.35(10), 4248–4257 (2015).
   PubMed Web of Science ®Google Scholar
• Arendt-Nielsen L , MorlionB , PerrotSet.al Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur. J. Pain22, 216–241 (2018).
   PubMed Web of Science ®Google Scholar
• Bannister K , BeeLA , DickensonAH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics6(4), 703–712 (2009).
   PubMed Web of Science ®Google Scholar
• Youssef AM , MacefieldVG , HendersonLA. Cortical influences on brainstem circuitry responsible for conditioned pain modulation in humans. Hum. Brain Mapp.37(7), 2630–2644 (2016).
   PubMed Web of Science ®Google Scholar
• Tzschentke TM , ChristophT , KögelBY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR–NRI) concept in analgesia: the case of tapentadol. CNS Drugs28(4), 319–329 (2014).
   PubMed Web of Science ®Google Scholar
• Tzschentke TM , ChristophT , KögelBet.al (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J. Pharmacol. Exp. Ther.323(1), 265–276 (2007).
   PubMed Web of Science ®Google Scholar
• Langford RM , KnaggsR , Farquhar-SmithP , DickensonAH. Is tapentadol different from classical opioids? A review of the evidence. Br. J. Pain10(4), 217–221 (2016).
   PubMed Web of Science ®Google Scholar
• Tzschentke TM , ChristophT , SchröderWet.al Tapentadol: mit zwei Mechanismen in einem Molekül wirksam gegen nozizeptive und neuropathische Schmerzen. Schmerz25, 19–25 (2011).
   PubMed Web of Science ®Google Scholar
• Schröder W , VryJD , TzschentkeTM , JahnelU , ChristophT. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur. J. Pain14(8), 814–821 (2010).
   PubMed Web of Science ®Google Scholar
• Raffa RB , EllingC , TzschentkeTM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘μ-load’. Adv. Ther.35(10), 1471–1484 (2018).
   PubMed Web of Science ®Google Scholar
• Kutch JJ , IchescoE , HampsonJPet.al ; MAPP Research Network. Brain signature and functional impact of centralized pain: a multidisciplinary approach to the study of chronic pelvic pain (MAPP) network study. Pain158(10), 1979–1991 (2017).
   PubMed Web of Science ®Google Scholar
• Ji RR , ChamessianA , ZhangYQ. Pain regulation by non-neuronal cells and inflammation. Science354(6312), 572–577 (2016).
   PubMed Web of Science ®Google Scholar
• Costigan M , ScholzJ , WoolfCJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci.32, 1–32 (2009).
   PubMed Web of Science ®Google Scholar
• Baron R . Mechanisms of disease: neuropathic pain – a clinical perspective. Nat. Clin. Pract. Neurol.2(2), 95–106 (2006).
   PubMedGoogle Scholar
• Thakur M , DickensonAH , BaronR. Osteoarthritis pain: nociceptive or neuropathic?Nat. Rev. Rheumatol.10(6), 374–380 (2014).
   PubMed Web of Science ®Google Scholar
• Raffa RB , PergolizziJVJr , TallaridaRJ. The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J. Pain11(8), 701–709 (2010).
   PubMed Web of Science ®Google Scholar
• Tzschentke TM , JahnelU , KogelBet.al Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc.)45(7), 483–496 (2009).
   PubMed Web of Science ®Google Scholar
• Romualdi P , GrilliM , CanonicoPL , CollinoM , DickensonAH. Pharmacological rationale for tapentadol therapy: a review of new evidence. J. Pain Res.12, 1513–1520 (2019).
   PubMed Web of Science ®Google Scholar
• Coluzzi F , PolatiE , FreoU , GrilliM. Tapentadol: an effective option for the treatment of back pain. J. Pain Res.12, 1521–1528 (2019).
   PubMed Web of Science ®Google Scholar
• Kress HG , ColuzziF. Tapentadol in the management of cancer pain: current evidence and future perspectives. J. Pain Res.12, 1553–1560 (2019).
   PubMed Web of Science ®Google Scholar
• Freo U , RomualdiP , KressHG. Tapentadol for neuropathic pain: a review of clinical studies. J. Pain Res.12, 1537–1551 (2019).
   PubMed Web of Science ®Google Scholar
• Rinonapoli G , CoaccioliS , PanellaL. Tapentadol in the treatment of osteoarthritis: pharmacological rationale and clinical evidence. J. Pain Res.12, 1529–1536 (2019).
   PubMed Web of Science ®Google Scholar
• Panella L , RinonapoliG , CoaccioliS. Where should analgesia lead to? Quality of life and functional recovery with tapentadol. J. Pain Res.12, 1561–1567 (2019).
   PubMed Web of Science ®Google Scholar
• Argoff CE , AlbrechtP , IrvingG , RiceF. Multimodal analgesia for chronic pain: rationale and future directions. Pain Med.10(Suppl. 2), S53–S66 (2009).
   PubMed Web of Science ®Google Scholar
• Els C , JacksonTD , KunykDet.al Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Database Syst. Rev.10, CD012509 (2017).
   PubMed Web of Science ®Google Scholar
• Polati E , CanonicoPL , SchweigerV , CollinoM. Tapentadol: an overview of the safety profile. J. Pain Res.12, 1569–1576 (2019).
   PubMed Web of Science ®Google Scholar
• Wild JE , GrondS , KuperwasserBet.al Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract.10(5), 416–427.
   PubMed Web of Science ®Google Scholar
• Finco G , MuraP , MusuM. Long-term oral tapentadol prolonged-release for the treatment of refractory chronic low back pain: a single-center, observational study. Minerva Med. (2018) ( In Press).
   PubMed Web of Science ®Google Scholar
• Baron R , KernU , MüllerM , DuboisC , FalkeD , SteigerwaldI. Effectiveness and tolerability of a moderate dose of tapentadol prolonged release for managing severe, chronic low back pain with a neuropathic component: an open-label continuation arm of a randomized Phase IIIb study. Pain Pract.15(5), 471–486 (2015).
   PubMed Web of Science ®Google Scholar
• Gomes T , TadrousM , MamdaniMM , PatersonJM , JuurlinkDN. The burden of opioid-related mortality in the United States. JAMA Netw. Open1(2), e180217 (2018).
   PubMed Web of Science ®Google Scholar
• Gracely RH , LynchSA , BennettGJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain51(2), 175–194 (1992).
   PubMed Web of Science ®Google Scholar
• Nau C , LeipoldE. Voltage-gated sodium channels and pain (2019). www.degruyter.com/view/j/nf.2017.23.issue-3/nf-2017-A017/nf-2017-A017.xml
   Google Scholar
• Dib-Hajj SD1 , WaxmanSG. Diversity of composition and function of sodium channels in peripheral sensory neurons. Pain156(12), 2406–2407 (2015).
   PubMed Web of Science ®Google Scholar
• Dickenson AH , PatelR. Sense and sensibility – logical approaches to profiling in animal models. Pain159(7), 1426–1428 (2018).
   PubMed Web of Science ®Google Scholar
• Vay L , GuC , McNaughtonPA. The thermo-TRP ion channel family: properties and therapeutic implications. Br. J. Pharmacol.165(4), 787–801 (2012).
   PubMed Web of Science ®Google Scholar
• Kremeyer B , LoperaF , CoxJJet.al A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron66(5), 671–680 (2010).
   PubMed Web of Science ®Google Scholar
• Sommer C , CruccuG. Topical treatment of peripheral neuropathic pain: applying the evidence. J. Pain Symptom Manage.53(3), 614–629 (2017).
   PubMed Web of Science ®Google Scholar
• Allegri M , BaronR , HansGet.al A pharmacological treatment algorithm for localized neuropathic pain. Curr. Med. Res. Opin.32, 377e384 (2016).
   Web of Science ®Google Scholar
• McKemy DD . How cold is it? TRPM8 and TRPA1 in the molecular logic of cold sensation. Mol. Pain1, 16 (2005).
   PubMed Web of Science ®Google Scholar
• Facer P , CasulaMA , SmithGDet.al Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol.7, 11 (2007).
   PubMed Web of Science ®Google Scholar
• Anand P , BleyK. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br. J. Anaesth.107(4), 490–502 (2011).
   PubMed Web of Science ®Google Scholar
• Anand P , ElsafaE , PriviteraRet.al Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J. Pain Res.12, 2039–2052 (2019).
   PubMed Web of Science ®Google Scholar
• Backonja M , WallaceMS , BlonskyERet.al ; NGX-4010 C116 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol.7(12), 1106–1112 (2008).
   PubMed Web of Science ®Google Scholar
• Irving GA , BackonjaMM , DuntemanEet.al ; NGX-4010 C117 Study Group. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med.12(1), 99–109 (2011).
   PubMed Web of Science ®Google Scholar
• Webster LR , TarkM , RauckR , TobiasJK , VanhoveGF. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol.10, 92 (2010).
   PubMed Web of Science ®Google Scholar
• Webster LR , MalanTP , TuchmanMM , MollenMD , TobiasJK , VanhoveGF. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J. Pain11(10), 972–982 (2010).
   PubMed Web of Science ®Google Scholar
• Clifford DB , SimpsonDM , BrownSet.al ; NGX-4010 C119 Study Group. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J. Acquir. Immune Defic. Syndr.59(2), 126–133 (2012).
   PubMed Web of Science ®Google Scholar
• Simpson DM , BrownS , TobiasJ; NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology70(24), 2305–2313 (2008).
   PubMed Web of Science ®Google Scholar
• Simpson DM , Robinson-PappJ , VanJet.al Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J. Pain.18(1), 42–53 (2017).
   PubMed Web of Science ®Google Scholar
• Gálvez R , NavezML , MoyleGet.al Capsaicin 8% patch repeat treatment in nondiabetic peripheral neuropathic pain: a 52-week, open-label, single-arm, safety study. Clin. J. Pain.33(10), 921–931 (2017).
   PubMed Web of Science ®Google Scholar
• Haanpää M , CruccuG , NurmikkoTJet.al Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur. J. Pain20(2), 316–328 (2016).
   PubMed Web of Science ®Google Scholar
• Cruccu G , NurmikkoTJ , ErnaultE , RiazFK , McBrideWT , HaanpääM. Superiority of capsaicin 8% patch versus oral pregabalin on dynamic mechanical allodynia in patients with peripheral neuropathic pain. Eur. J. Pain22(4), 700–706 (2018).
   PubMed Web of Science ®Google Scholar
• Mankowski C , PooleCD , ErnaultEet.al Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol.17(1), 80 (2017).
   PubMedGoogle Scholar
• Maihofner C , HeskampML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr. Med. Res. Opin.29(6), 673–683 (2013).
   PubMed Web of Science ®Google Scholar
• Hansson P , JensenTS , KvarsteinG , StrömbergM. Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice. Eur. J. Pain22(5), 941–950 (2018).
   PubMed Web of Science ®Google Scholar
• Navez ML , MonellaC , BöslI , SommerD , DelormeC. 5% lidocaine medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability. Pain Ther.4(1), 1–15 (2015).
   PubMed Web of Science ®Google Scholar
• Sabatowski R , BöslI , KönigS , BuchheisterB , MeierT , BaronR. Treatment of postherpetic neuralgia with 5% lidocaine medicated plaster in elderly patients – subgroup analyses from three European clinical trials. Curr. Med. Res. Opin.33(3), 595–603 (2017).
   PubMed Web of Science ®Google Scholar
• Finnerup NB , AttalN , HaroutounianSet.al Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol.14(2), 162–173 (2015).
   PubMed Web of Science ®Google Scholar
• Attal N , CruccuG , BaronRet.al ; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol.17(9), 1113–e88 (2010).
   PubMed Web of Science ®Google Scholar
• Dubinsky RM , KabbaniH , El-ChamiZ , BoutwellC , AliH; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology63(6), 959–65 (2004).
   PubMed Web of Science ®Google Scholar
• Baron R , MayoralV , LeijonG , BinderA , SteigerwaldI , SerpellM. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr. Med. Res. Opin.25(7), 1663–1676 (2009).
   PubMed Web of Science ®Google Scholar
• Sabatowski R , HansG , TackenI , KapanadzeS , BuchheisterB , BaronR. Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia. Curr. Med. Res. Opin.28(8), 1337–1346 (2012).
   PubMed Web of Science ®Google Scholar
• Martini A , DelBalzo G , SchweigerVet.al Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy. Minerva Med.109(5), 344–351 (2018).
   PubMed Web of Science ®Google Scholar
• Clère F , Delorme-MorinC , GeorgeBet.al 5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia: results of a compassionate use programme in France. Drugs Aging28(9), 693–702 (2011).
   PubMed Web of Science ®Google Scholar
• Baron R , AllegriM , Correa-IllanesGet.al The 5% lidocaine-medicated plaster: its inclusion in international treatment guidelines for treating localized neuropathic pain, and clinical evidence supporting its use. Pain Ther.5(2), 149–169 (2016).
   PubMedGoogle Scholar